Cargando…
The Patient’s Point of View: COVID-19 and Neuroendocrine Tumor Disease
SIMPLE SUMMARY: Since neuroendocrine tumor patients require a highly specialized and interdisciplinary infrastructure for diagnostic and therapy, medical care has been very challenging during the COVID-19 pandemic. In cooperation with the patient organization NETZWERK NeT we were able to distribute...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833713/ https://www.ncbi.nlm.nih.gov/pubmed/35158882 http://dx.doi.org/10.3390/cancers14030613 |
_version_ | 1784649012363657216 |
---|---|
author | Krug, Sebastian Khosravian, Maryam Weissbach, Julia George, Katharina Damm, Marko Garbe, Jakob Walldorf, Jens Reuken, Philipp A. Amin, Tania Siebenhüner, Alexander Rosendahl, Jonas Gress, Thomas M. Michl, Patrick Schrader, Jörg Rinke, Anja |
author_facet | Krug, Sebastian Khosravian, Maryam Weissbach, Julia George, Katharina Damm, Marko Garbe, Jakob Walldorf, Jens Reuken, Philipp A. Amin, Tania Siebenhüner, Alexander Rosendahl, Jonas Gress, Thomas M. Michl, Patrick Schrader, Jörg Rinke, Anja |
author_sort | Krug, Sebastian |
collection | PubMed |
description | SIMPLE SUMMARY: Since neuroendocrine tumor patients require a highly specialized and interdisciplinary infrastructure for diagnostic and therapy, medical care has been very challenging during the COVID-19 pandemic. In cooperation with the patient organization NETZWERK NeT we were able to distribute a comprehensive survey, which has profoundly investigated the healthcare structure and patient-specific concerns during the crisis. In addition to regular medical care, there is a considerable need to measure patient-reported outcomes such as social and emotional distress in a structured way to optimize individual therapy for NET patients. ABSTRACT: The assessment of cancer patient care during the COVID-19 pandemic has been mainly reported from a physician’s perspective. Patients with rare tumor entities such as neuroendocrine tumors (NET), which require a complex and specialized care infrastructure, were highly affected by the COVID-19 crisis. Using a structured questionnaire consisting of a general section on the disease and a special COVID-19 section to record medical care, vaccination behavior as well as social and psycho-emotional parameters were collected from NET patients. The survey was distributed via direct medical contact and via the patient organization NETZWERK NeT. A total of 684 patients participated in the survey and 79.2% (n = 542) of the participants answered the questionnaire completely (54 questions). Patient characteristics were comparable to those in large NET registries. The majority of participants were patients with pancreatic and small bowel NET on somatostatin analogue (SSA) therapy. Medical care under COVID-19 was adequate and appointment cancellations and postponements were not common. Nevertheless, the majority of patients were worried about adequate treatment for their tumor disease during the crisis. Most of the participants considered themselves to be at risk of severe COVID-19 infection and were therefore very concerned. This was accompanied by an extremely high vaccination readiness rate of 90%. Increased distress in the social and psycho-emotional domains in the course of the crisis reflected a need for optimization in the medical care of NET patients, although the rate of COVID-19 positive participants was low (3.7%). Therefore, patient-reported measurements are required to identify and address all areas of medical care. Overall, our survey provides an essential contribution to the care of NET patients during the COVID-19 pandemic from the patient’s perspective. |
format | Online Article Text |
id | pubmed-8833713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88337132022-02-12 The Patient’s Point of View: COVID-19 and Neuroendocrine Tumor Disease Krug, Sebastian Khosravian, Maryam Weissbach, Julia George, Katharina Damm, Marko Garbe, Jakob Walldorf, Jens Reuken, Philipp A. Amin, Tania Siebenhüner, Alexander Rosendahl, Jonas Gress, Thomas M. Michl, Patrick Schrader, Jörg Rinke, Anja Cancers (Basel) Article SIMPLE SUMMARY: Since neuroendocrine tumor patients require a highly specialized and interdisciplinary infrastructure for diagnostic and therapy, medical care has been very challenging during the COVID-19 pandemic. In cooperation with the patient organization NETZWERK NeT we were able to distribute a comprehensive survey, which has profoundly investigated the healthcare structure and patient-specific concerns during the crisis. In addition to regular medical care, there is a considerable need to measure patient-reported outcomes such as social and emotional distress in a structured way to optimize individual therapy for NET patients. ABSTRACT: The assessment of cancer patient care during the COVID-19 pandemic has been mainly reported from a physician’s perspective. Patients with rare tumor entities such as neuroendocrine tumors (NET), which require a complex and specialized care infrastructure, were highly affected by the COVID-19 crisis. Using a structured questionnaire consisting of a general section on the disease and a special COVID-19 section to record medical care, vaccination behavior as well as social and psycho-emotional parameters were collected from NET patients. The survey was distributed via direct medical contact and via the patient organization NETZWERK NeT. A total of 684 patients participated in the survey and 79.2% (n = 542) of the participants answered the questionnaire completely (54 questions). Patient characteristics were comparable to those in large NET registries. The majority of participants were patients with pancreatic and small bowel NET on somatostatin analogue (SSA) therapy. Medical care under COVID-19 was adequate and appointment cancellations and postponements were not common. Nevertheless, the majority of patients were worried about adequate treatment for their tumor disease during the crisis. Most of the participants considered themselves to be at risk of severe COVID-19 infection and were therefore very concerned. This was accompanied by an extremely high vaccination readiness rate of 90%. Increased distress in the social and psycho-emotional domains in the course of the crisis reflected a need for optimization in the medical care of NET patients, although the rate of COVID-19 positive participants was low (3.7%). Therefore, patient-reported measurements are required to identify and address all areas of medical care. Overall, our survey provides an essential contribution to the care of NET patients during the COVID-19 pandemic from the patient’s perspective. MDPI 2022-01-26 /pmc/articles/PMC8833713/ /pubmed/35158882 http://dx.doi.org/10.3390/cancers14030613 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Krug, Sebastian Khosravian, Maryam Weissbach, Julia George, Katharina Damm, Marko Garbe, Jakob Walldorf, Jens Reuken, Philipp A. Amin, Tania Siebenhüner, Alexander Rosendahl, Jonas Gress, Thomas M. Michl, Patrick Schrader, Jörg Rinke, Anja The Patient’s Point of View: COVID-19 and Neuroendocrine Tumor Disease |
title | The Patient’s Point of View: COVID-19 and Neuroendocrine Tumor Disease |
title_full | The Patient’s Point of View: COVID-19 and Neuroendocrine Tumor Disease |
title_fullStr | The Patient’s Point of View: COVID-19 and Neuroendocrine Tumor Disease |
title_full_unstemmed | The Patient’s Point of View: COVID-19 and Neuroendocrine Tumor Disease |
title_short | The Patient’s Point of View: COVID-19 and Neuroendocrine Tumor Disease |
title_sort | patient’s point of view: covid-19 and neuroendocrine tumor disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833713/ https://www.ncbi.nlm.nih.gov/pubmed/35158882 http://dx.doi.org/10.3390/cancers14030613 |
work_keys_str_mv | AT krugsebastian thepatientspointofviewcovid19andneuroendocrinetumordisease AT khosravianmaryam thepatientspointofviewcovid19andneuroendocrinetumordisease AT weissbachjulia thepatientspointofviewcovid19andneuroendocrinetumordisease AT georgekatharina thepatientspointofviewcovid19andneuroendocrinetumordisease AT dammmarko thepatientspointofviewcovid19andneuroendocrinetumordisease AT garbejakob thepatientspointofviewcovid19andneuroendocrinetumordisease AT walldorfjens thepatientspointofviewcovid19andneuroendocrinetumordisease AT reukenphilippa thepatientspointofviewcovid19andneuroendocrinetumordisease AT amintania thepatientspointofviewcovid19andneuroendocrinetumordisease AT siebenhuneralexander thepatientspointofviewcovid19andneuroendocrinetumordisease AT rosendahljonas thepatientspointofviewcovid19andneuroendocrinetumordisease AT gressthomasm thepatientspointofviewcovid19andneuroendocrinetumordisease AT michlpatrick thepatientspointofviewcovid19andneuroendocrinetumordisease AT schraderjorg thepatientspointofviewcovid19andneuroendocrinetumordisease AT rinkeanja thepatientspointofviewcovid19andneuroendocrinetumordisease AT krugsebastian patientspointofviewcovid19andneuroendocrinetumordisease AT khosravianmaryam patientspointofviewcovid19andneuroendocrinetumordisease AT weissbachjulia patientspointofviewcovid19andneuroendocrinetumordisease AT georgekatharina patientspointofviewcovid19andneuroendocrinetumordisease AT dammmarko patientspointofviewcovid19andneuroendocrinetumordisease AT garbejakob patientspointofviewcovid19andneuroendocrinetumordisease AT walldorfjens patientspointofviewcovid19andneuroendocrinetumordisease AT reukenphilippa patientspointofviewcovid19andneuroendocrinetumordisease AT amintania patientspointofviewcovid19andneuroendocrinetumordisease AT siebenhuneralexander patientspointofviewcovid19andneuroendocrinetumordisease AT rosendahljonas patientspointofviewcovid19andneuroendocrinetumordisease AT gressthomasm patientspointofviewcovid19andneuroendocrinetumordisease AT michlpatrick patientspointofviewcovid19andneuroendocrinetumordisease AT schraderjorg patientspointofviewcovid19andneuroendocrinetumordisease AT rinkeanja patientspointofviewcovid19andneuroendocrinetumordisease |